438 related articles for article (PubMed ID: 28131727)
21. Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease.
Cordero-Llana Ó; Houghton BC; Rinaldi F; Taylor H; Yáñez-Muñoz RJ; Uney JB; Wong LF; Caldwell MA
Mol Ther; 2015 Feb; 23(2):244-54. PubMed ID: 25369767
[TBL] [Abstract][Full Text] [Related]
22. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
23. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
[TBL] [Abstract][Full Text] [Related]
24. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.
Rosenblad C; Martinez-Serrano A; Björklund A
Neuroscience; 1998 Jan; 82(1):129-37. PubMed ID: 9483509
[TBL] [Abstract][Full Text] [Related]
25. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
Smith AD; Kozlowski DA; Bohn MC; Zigmond MJ
Exp Neurol; 2005 Jun; 193(2):420-6. PubMed ID: 15869944
[TBL] [Abstract][Full Text] [Related]
26. Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats.
Renko JM; Bäck S; Voutilainen MH; Piepponen TP; Reenilä I; Saarma M; Tuominen RK
Mol Neurobiol; 2018 Aug; 55(8):6755-6768. PubMed ID: 29349573
[TBL] [Abstract][Full Text] [Related]
27. Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats.
Suzuki S; Kawamata J; Iwahara N; Matsumura A; Hisahara S; Matsushita T; Sasaki M; Honmou O; Shimohama S
Neurosci Lett; 2015 Jan; 584():276-81. PubMed ID: 25449872
[TBL] [Abstract][Full Text] [Related]
28. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
[TBL] [Abstract][Full Text] [Related]
29. Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease.
Duan D; Yang H; Zhang J; Zhang J; Xu Q
Exp Brain Res; 2005 Mar; 161(3):316-24. PubMed ID: 15480595
[TBL] [Abstract][Full Text] [Related]
30. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
Ericson C; Georgievska B; Lundberg C
Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109
[TBL] [Abstract][Full Text] [Related]
31. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Kirik D; Georgievska B; Rosenblad C; Björklund A
Eur J Neurosci; 2001 Apr; 13(8):1589-99. PubMed ID: 11328352
[TBL] [Abstract][Full Text] [Related]
32. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease.
Garbayo E; Ansorena E; Lanciego JL; Blanco-Prieto MJ; Aymerich MS
Mov Disord; 2011 Aug; 26(10):1943-7. PubMed ID: 21661048
[TBL] [Abstract][Full Text] [Related]
33. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo.
Sullivan AM; Opacka-Juffry J; Blunt SB
Eur J Neurosci; 1998 Jan; 10(1):57-63. PubMed ID: 9753113
[TBL] [Abstract][Full Text] [Related]
34. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI
Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Kobayashi K; Takeuchi A; Yano A; Muraoka K; Matsui T; Miyoshi Y; Hamada H; Date I
Eur J Neurosci; 2004 Mar; 19(6):1494-504. PubMed ID: 15066146
[TBL] [Abstract][Full Text] [Related]
38. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Cunningham LA; Su C
Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
[TBL] [Abstract][Full Text] [Related]
39. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons.
Bowenkamp KE; Hoffman AF; Gerhardt GA; Henry MA; Biddle PT; Hoffer BJ; Granholm AC
J Comp Neurol; 1995 May; 355(4):479-89. PubMed ID: 7636027
[TBL] [Abstract][Full Text] [Related]
40. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration.
Natsume A; Mata M; Goss J; Huang S; Wolfe D; Oligino T; Glorioso J; Fink DJ
Exp Neurol; 2001 Jun; 169(2):231-8. PubMed ID: 11358438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
